Seres Therapeutics, Inc. (MCRB) Stock Price & Analysis
Seres Therapeutics, Inc. (MCRB) fell 5.07% to USD 4.97 as of July 25, 2026 at 07:30 UTC, according to Nexqual real-time market data.
MCRB last closed at USD 5.23; the session ranged USD 4.93–5.44 on volume of 81,825 shares. Market capitalization is $48.08M, with a 52-week range of USD 4.92–29.98 (NMS). Source: Nexqual, July 25, 2026 at 07:30 UTC.
Key Statistics (as of July 25, 2026 at 07:30 UTC)
| Price | USD 4.97 |
|---|---|
| Change | ▼ 5.07% (down) |
| Previous Close | USD 5.23 |
| Open | USD 5.22 |
| Day Range | USD 4.93 – 5.44 |
| 52-Week Range | USD 4.92 – 29.98 |
| Volume | 81,825 shares |
| Market Cap | $48.08M |
| Exchange | NMS |
Technical Analysis (MCRB)
Nexqual's technical model rates MCRB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:30 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.03 (neutral) |
| vs SMA50 | Below (USD 6.76) |
| MACD | -0.54 (negative) |
Analyst Ratings (MCRB)
Wall Street analysts rate MCRB "None" based on 2 analysts, with a mean price target of USD 17 (range USD 12–22), per Nexqual as of July 25, 2026 at 07:30 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17 |
| High Target | USD 22 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (MCRB)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -2.19 |
| Revenue Estimate | $179,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.08 vs est -1.88 ▼ miss |
| 2025-12-31 | USD -1.76 vs est -1.6 ▼ miss |
| 2025-09-30 | USD 0.94 vs est 1.28 ▼ miss |
| 2025-06-30 | USD -2.27 vs est -2.28 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:30 UTC.
Financials & Fundamentals (MCRB)
| Total Revenue | $1.15M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -5839.94% |
| Profit Margin | +0.00% |
| ROE | -121.87% |
| Debt / Equity | 303.78 |
| Current Ratio | 1.65 |
| Total Cash | $29.83M |
| Total Debt | $80.50M |
| Free Cash Flow | $-41.54M |
Source: Nexqual, July 25, 2026 at 07:30 UTC.
Financial Health Score (MCRB)
Nexqual rates Seres Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $30M cash vs $80M debt |
| Cash Flow | Weak — FCF negative: -$42M, burning cash |
| Efficiency | Critical — ROE -122%, ROA -38.9% |
Ownership (MCRB)
| Insider Ownership | +11.78% |
|---|---|
| Institutional Ownership | +23.98% |
| Shares Outstanding | 9.68M |
| Float | 8.47M |
| Short % of Float | +4.10% |
Source: Nexqual, July 25, 2026 at 07:30 UTC.
Leadership (MCRB)
Seres Therapeutics, Inc. is led by Richard N. Kender B.S. (age 69), Interim CEO & Executive Chair, per Nexqual as of July 25, 2026 at 07:30 UTC.
| Interim CEO & Executive Chair | Richard N. Kender B.S. (age 69) |
|---|---|
| President & Chief Scientific Officer | Matthew R. Henn (age 50) |
| Executive VP, CFO & Treasurer | Marella Thorell (age 58) |
| Executive VP & COO | Kelly Brady M.S. (age 41) |
| Executive VP & CTO | Chris McChalicher |
Major Backers & Investors (MCRB)
Notable institutional backers of Seres Therapeutics, Inc. include Flagship Pioneering LLC, Marshall Wace LLP, Vontobel Holding Limited, according to Nexqual as of July 25, 2026 at 07:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flagship Pioneering LLC | 11.94% |
| Marshall Wace LLP | 1.44% |
| Vontobel Holding Limited | 1.43% |
| Susquehanna International Group, LLP | 1.09% |
| American Century Companies Inc | 0.9% |
| Fidelity | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.45% |
| BlackRock | 1.22% |
| Geode Capital | 0.77% |
| State Street | 0.35% |
Source: Nexqual, July 25, 2026 at 07:30 UTC.
From Seres Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
- The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
- It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| FATE | Fate Therapeutics, Inc. | USD 2.41 | ▼ 6.59% |
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 4.99 | ▼ 3.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:30 UTC. This page is informational and not investment advice.